 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| • |
e4/e4 AD patients show markedly more APP
|
|
|
deposition in plaques relative to non-e4 AD
|
|
|
patients
|
|
|
| • |
ApoE e4 binds BA4 peptide with greater avidity
|
|
|
than e3 isoform.
|
|
|
| • |
ApoE e4 shows significant allelic association in
|
|
|
familial and sporadic late onset
AD, and in familial
|
|
early onset AD.
|
|
|
|
– |
e4 heterozygote is 3X more likely to be affected than
e2/e3
|
|
or e3/e3
|
|
|
|
– |
e4 homozygote is 8X more likely to be affected
|
|
|
Conclusion: ApoE e4 gene dose is a major
risk factor
|
|
|
for late (and possibly early) onset AD. Inheritance
|
|
|
of two e4 alleles is not
necessary and probably not
|
|
|
sufficient to cause AD.
|
|